The National Institutes of Health teamed with Dow Chemical in a four-year research deal focused on creating new plant-based vaccines using genetically engineered plants. The technology is also being studied as a potential source of low-cost pharmaceuticals to treat everything from Crohn's disease to hospital-acquired infections.